Haemoptysis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 04:06:22 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Haemoptysis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Tranexamic Acid and Terlipressin for Emergency Treatment of Mild to Severe Hemoptysis in Patients Without Cystic Fibrosis https://clinicaltrials.eu/trial/study-on-tranexamic-acid-and-terlipressin-for-emergency-treatment-of-mild-to-severe-hemoptysis-in-patients-without-cystic-fibrosis/ Wed, 29 Apr 2026 14:23:16 +0000 https://clinicaltrials.eu/trial/study-on-tranexamic-acid-and-terlipressin-for-emergency-treatment-of-mild-to-severe-hemoptysis-in-patients-without-cystic-fibrosis/ This clinical trial is focused on studying the treatment of hemoptysis, which is the coughing up of blood from the lungs or airways. The trial will explore the effectiveness of two medications: tranexamic acid and terlipressin. Both medications will be administered through inhalation, which means they are breathed in using a device called a nebulizer. The purpose of the study is to determine how well these treatments can control mild to severe hemoptysis in patients during the first three days of hospitalization.

Participants in the study will receive either tranexamic acid, terlipressin, or a placebo, which is a substance with no active medication. The trial will monitor the patients to see if the hemoptysis resolves completely or partially without needing any additional medical procedures. Complete resolution means the bleeding stops entirely within three days, while partial resolution means the bleeding reduces significantly.

The study will also track other outcomes, such as the total amount of blood coughed up, the need for further treatments, and any side effects that may occur. This information will help researchers understand the potential benefits and risks of using these medications for treating hemoptysis. The trial is expected to continue until early 2026, with the goal of providing valuable insights into the management of this condition.

]]>